

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission

7*

Application Number	09/580,015 ✓	RECEIVED C ENTR AL P R O C E S S O N O V E M B E R 1 6 0 0 /2 9 0
Filing Date	May 26, 2000	
First Named Inventor	Schenk, Dale B.	
Group Art Unit	1647	
Examiner Name	Turner, Sharon	

Attorney Docket Number 15270J-004750US


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Return Postcard (1pg)
<input checked="" type="checkbox"/> Information Disclosure Statement (2 pp) w/attached PTO/SB/08A (1 pg) and PTO/SB/08B (2 pp) w/2 volumes of references* (nos. 304-326)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		* Note: References not included in total number of pages.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm and Individual name	Townsend and Townsend and Crew LLP Rosemarie L. Celli	
Signature		
Date	October 14, 2002	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service, Technical Center 1600, VIA HAND DELIVERY addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

10/15/02

Typed or printed name	Heather Savia	
Signature		Date 10/15/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3257084 v1

RECEIVED
TECH CENTER 1600/2900

OCT 18 2002

RECEIVED

I hereby certify that this correspondence is being delivered by
Hand Delivery to:

Group 1600
Assistant Commissioner for Patents
Washington, D.C. 20231

On October 15 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Heather Savia

PATENT
Attorney Docket No.: 15270J-004750US
Client Reference No.: 209-US-CIP&A

02 OCT 15 PM 1:39
RECEIVED
TECH CENTER 1600/2900

RECEIVED

OCT 18 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DALE B. SCHENK

Application No.: 09/580,015

Filed: May 26, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon

Art Unit: 1647

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The references cited on attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference

should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:rms

PA 3257115 v 1

Substitute for form 1449B/PTO				Complete if Known Application Number 09/580,015 Filing Date May 25, 2000 First Named Inventor Schenk, Dale B. Art Unit 1647 Examiner Name Sharon Turner Attorney Docket Number 15270J-004750US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>					
Sheet	1	of	3		

RECEIVED
MAY 2000
1600
2900

U.S. PATENT DOCUMENTS				
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
305		09/724,842	11-28-2000	Chalifour et al.
326		2002/0136718 A1	09-26-2002	Raso
325		2001/0102261 A1	08-01-2002	Raso
306		6,417,178 B1	07-09-2002	Klunk et al.
321		5,837,672	11-17-1998	Schenk et al.
320		5,593,846	01-14-1997	Schenk et al.

RECEIVED

OCT 18 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document
		Country Code ³	Number ⁴ Kind Code ⁴ (if known)		
322		PCT	00/72880 A2, A3	12-07-2000	
323		PCT	00/72876 A2, A3	12-07-2000	
324		PCT	00/72870 A1	12-07-2000	

Examiner Signature		Date Considered
-----------------------	--	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3257077 v1

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				OCT 15 PM 1:39	RECEIVED U.S. PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900
(use as many sheets as necessary)					
Sheet	2	of	3	Attorney Docket Number	15270J-004750US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	307	CHEN, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. <i>Nature</i> . 408(6815):975-9 (2000).
	318	DU, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. <i>Neurology</i> . 57(5):801-5 (2001).
	308	JANUS, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. <i>Nature</i> . 408(6815):979-82 (2000).
	309	MATTSON, MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. <i>Physiol Rev</i> . 77(4):1081-132 (1997).
	310	MERLUZZI, et al. Humanized antibodies as potential drugs for therapeutic use. <i>Adv Clin Path</i> . 4(2):77-85 (2000).
	311	MORGAN, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. <i>Nature</i> . 408(6815):982-5 (2000).
	304	RASO, V.A., Grant application # 1 R43 AGI 5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).
	312	SCHENK, et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. <i>DNA Cell Biol</i> . 20(11):679-81 (2001).
	313	SELKOE, DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. <i>Trends Cell Biol</i> . 8(11):447-53 (1998).
	314	SIGURDSSON, et al. In vivo reversal of amyloid-beta lesions in rat brain. <i>J Neuropathol Exp Neurol</i> . 59(1):11-17 (2000).
	315	SINHA, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. <i>Ann N Y Acad Sci</i> . 920:206-8 (2000).

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3257077 v 1
PA 3255579 v 2

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
TECH CENTER 1600/2900
OCT 18 2002

TECH CENTER 1600/2900
02 01 1600/2900
PA 11:39

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete If Known

Application Number	09/580,015
Filing Date	May 25, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Sharon Turner
Attorney Docket Number	15270J-004750US

	319	SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2(8):595-8 (2001).
	316	SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 4(7):822-6 (1998).
	317	VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. DNA Cell Biol. (11):713-21 (2001).

OCT 18 2002

RECEIVED

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional).² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3257077 v 1
PA 3255579 v 2